Home
Scholarly Works
First-Line Monotherapy With Nivolumab (Anti-PD-1;...
Conference

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status Metastatic Non-Small Cell Lung Cancer

Authors

Rizvi NA; Shepherd FA; Antonia SJ; Brahmer JR; Chow LQ; Goldman J; Juergens R; Borghaei H; Ready NE; Gerber DE

Volume

90

Publisher

Elsevier

Publication Date

November 15, 2014

DOI

10.1016/j.ijrobp.2014.08.204

Conference proceedings

International Journal of Radiation Oncology • Biology • Physics

Issue

5

ISSN

0360-3016

Contact the Experts team